GLP-1 for Smoking Cessation: Chantix, Bupropion, and Nicotine Stacking

About 12% of US adults still smoke, and most of them have tried to quit at least once. The two FDA-approved first-line pharmacotherapies — varenicline (Chantix) and bupropion SR (Zyban) — produce 12-week continuous abstinence rates of roughly 25% and 18% in the registration trials (Jorenby 2006 JAMA^[5], Hurt 1997 NEJM^[6]). Combined with nicotine replacement, varenicline pushes higher still (Stead 2016 Cochrane^[8]). GLP-1 receptor agonists have entered this conversation because the same mesolimbic reward pathway that drives food craving also drives nicotine craving — and the published signal, while still early, is consistent. Wang 2024 (Annals of Internal Medicine^[1]) found a 32% lower risk of tobacco-use-disorder relapse on semaglutide vs other diabetes drugs in a target-trial emulation of more than 200,000 patients. Yammine 2021 (Nicotine and Tobacco Research^[2]) randomized 84 treatment- seeking smokers to exenatide plus a nicotine patch vs nicotine patch alone and reported higher continuous abstinence in the exenatide arm. This article walks through what the evidence does and does not yet show, and how a smoker with obesity might coordinate a quit attempt with a GLP-1 dose ladder.

The honest summary

• The reward-pathway hypothesis is biologically plausible. GLP-1 receptors are expressed in the ventral tegmental area and nucleus accumbens — the same dopaminergic circuit activated by nicotine. Preclinical models show GLP-1 receptor activation reduces nicotine self-administration; the Herman 2024 review^[4] summarizes the bench-to-bedside translation.
• Real-world signal is consistent. Wang 2024^[1] found a 32% reduction in tobacco-use-disorder relapse on semaglutide vs other diabetes drugs in a target- trial emulation; the signal was directionally similar across DPP-4 inhibitors, SGLT-2 inhibitors, and insulin comparators.
• Randomized data is still small. Yammine 2021^[2] was a 12-week pilot RCT (n=84) of exenatide plus nicotine patch; the follow-up Yammine 2025 predictors paper^[3] identified baseline nicotine dependence and weight as response modifiers but the definitive Phase 3 program has not been published.
• First-line therapy is still varenicline or bupropion SR plus NRT. Jorenby 2006^[5], Hurt 1997^[6], Anthenelli 2016 (EAGLES^[7]), and Stead 2016^[8] establish the 18–28% 12-month abstinence floor that any GLP-1 add-on has to clear.

The pharmacotherapy baseline: what already works

Smoking-cessation pharmacology is one of the most thoroughly studied areas in modern medicine. The Cahill 2013 Cochrane network meta-analysis^[9] pooled 267 trials and ranked the agents by 6–12 month continuous abstinence:

• Self-quit (no treatment): roughly 3–5% 12-month abstinence.
• Nicotine replacement (single product): patch, gum, lozenge, inhaler, or nasal spray, about 14% continuous abstinence at 12 months.
• Bupropion SR 300 mg/day: 18% at 12 months in Hurt 1997^[6], replicated as 17.7% in Jorenby 2006^[5].
• Combination NRT (patch + short-acting): about 24% at 12 months in Stead 2016^[8]; the patch supplies baseline plasma nicotine while the gum, lozenge, or inhaler covers acute cravings.
• Varenicline 1 mg twice daily: 25.4% at 12 months in Jorenby 2006^[5] and confirmed safe in EAGLES^[7] in patients with and without psychiatric disorders.
• Varenicline plus bupropion SR: roughly 30% at 12 months in head-to-head augmentation trials; not always better than varenicline alone but well tolerated.

Varenicline was briefly withdrawn from the US market in 2021 after Pfizer detected N-nitroso-varenicline (NDMA-class) impurities above acceptable limits. FDA-approved generic varenicline returned to US pharmacies in 2022–2023, and the agent remains the most effective single drug for smoking cessation. Brand Chantix is no longer commercially marketed in the US; generic varenicline costs roughly $100–150 per 12-week course at most pharmacies.

The Wang 2024 real-world cohort: semaglutide and tobacco use disorder

The strongest currently-published signal that GLP-1 medications affect nicotine use comes from Wang 2024 in the Annals of Internal Medicine^[1]. The investigators used the TriNetX electronic health record network to construct a target- trial emulation comparing patients with type 2 diabetes plus comorbid tobacco use disorder who were newly started on semaglutide vs newly started on seven comparator diabetes drugs (insulin, metformin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas, thiazolidinediones, and other GLP-1 receptor agonists). Across more than 200,000 propensity-matched comparisons, semaglutide was associated with significantly lower one-year risk of:

• Medical encounters for tobacco use disorder (hazard ratio approximately 0.68 vs insulin; comparable reductions vs other classes).
• Smoking-cessation prescriptions (a proxy for active quit attempts that fail and require pharmacotherapy escalation).
• Smoking-cessation counseling visits.

Target-trial emulation reduces but does not eliminate confounding by indication, and the analysis cannot prove causation. What it does show is that, within a real-world population of smokers with diabetes, those who start semaglutide show meaningfully fewer downstream signals of active tobacco use over the next year. The effect is directionally similar across all comparator classes, which argues against a residual-confounding artifact tied to any single class.

The Yammine exenatide pilot trial

Yammine 2021^[2] is the only randomized GLP-1 vs placebo smoking-cessation trial published to date. The investigators enrolled 84 treatment-seeking adult smokers without diabetes; all received a nicotine patch and 12 weeks of behavioral counseling, and were randomized to exenatide 2 mg weekly or placebo injection. End-of-treatment 7-day point-prevalence abstinence was 46.3% on exenatide vs 26.8% on placebo (P=0.06), and continuous abstinence over the final 4 weeks was numerically higher in the exenatide arm. The trial was underpowered for a definitive estimate, but the direction and effect size are consistent with the Wang real-world cohort. Yammine 2025^[3] followed up by analyzing treatment-response predictors and identified higher baseline nicotine dependence and higher baseline weight as the characteristics most associated with response to GLP-1 receptor agonist treatment for smoking.

The mechanistic review from Herman 2024^[4] ties the clinical signal back to the dopaminergic reward circuitry: GLP-1 receptor agonists reduce dopamine release in the nucleus accumbens in response to both food and nicotine cues, which is the shared substrate driving both food noise and nicotine craving. The same circuit explains the alcohol-use-disorder signal we covered in the GLP-1 and alcohol use disorder evidence review and the naltrexone stacking story in the GLP-1 and naltrexone stacking review.

Magnitude: 12-month abstinence by intervention

The practical protocol for a smoker starting a GLP-1

Most smokers presenting for GLP-1 therapy already have obesity and are already worried about post-cessation weight gain (typically 5–10 lb in the first 12 months). The attractive feature of a GLP-1 plus smoking-cessation stack is that the GLP-1 blunts the weight-gain side of quitting while potentially augmenting the cessation pharmacotherapy. The published evidence does not yet justify GLP-1 monotherapy for smoking cessation — first-line is still varenicline or bupropion SR plus NRT, and GLP-1 is an adjunct. A reasonable coordinated protocol:

1. Set a quit date 4–6 weeks into GLP-1 titration. The first month on Wegovy or Zepbound is the appetite-adjustment window; quit dates set during that window risk overlapping nausea with nicotine withdrawal. Week 5–6 of the GLP-1 ladder is a calmer landing spot.
2. Start varenicline 7 days before the quit date. Titrate 0.5 mg daily for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily through week 12. EAGLES^[7] confirmed that varenicline is safe in patients with and without psychiatric disorders — the earlier neuropsychiatric boxed warning was removed by the FDA in 2016.
3. Or bupropion SR 150 mg daily for 3 days, then 150 mg twice daily. Start 7 days before the quit date, continue 7–12 weeks. Contraindicated in seizure disorder, current or prior bulimia or anorexia, and concurrent MAOI use. See our GLP-1 and Wellbutrin stacking review for the full safety profile when paired with a GLP-1.
4. Add NRT. Combination NRT (a 21 mg patch plus a short-acting gum, lozenge, or inhaler) is the most effective NRT regimen per Stead 2016^[8]. The patch supplies baseline plasma nicotine; the short-acting form covers breakthrough cravings.
5. Track CO breath measurements. A handheld carbon-monoxide meter at each clinic visit provides objective abstinence confirmation; expired CO drops from 15–25 ppm (active smoker) to under 6 ppm within 24 hours of the last cigarette.
6. Use a quit line. 1-800-QUIT-NOW connects callers to free state-funded counseling and, in many states, free starter NRT. Combined pharmacotherapy plus behavioral counseling produces better abstinence than either alone in Stead 2016^[8].

E-cigarettes, vaping, and pregnancy

The same protocol applies to vaping cessation. There is no FDA-approved vaping-specific cessation drug, but varenicline, bupropion SR, and NRT are all considered acceptable off-label for e-cigarette use; the underlying nicotine dependence pharmacology is identical. For patients planning pregnancy, the recommendation is to stop the GLP-1 at least 8 weeks before conception (the standard washout for semaglutide) and to use NRT rather than varenicline or bupropion if cold-turkey cessation is not feasible — NRT during pregnancy is the preferred ACOG and US Preventive Services Task Force position.

Cost and access

Smoking-cessation pharmacotherapy is widely covered. Most US commercial insurance, Medicaid, and Medicare Part D plans cover varenicline, bupropion SR, and at least one NRT product with zero or low cost share under the Affordable Care Act preventive-services rule. Cash prices: generic varenicline about $100–150 per 12-week course; bupropion SR generic about $20–30 per month; OTC NRT roughly $50–150 per month depending on combination. Quit-line counseling through 1-800-QUIT-NOW is free in all US states and territories. GLP-1 medications are not covered for smoking cessation specifically — coverage continues to be tied to the FDA-approved obesity or diabetes indication.

Related research and tools

• GLP-1 and Wellbutrin (bupropion) stacking — the safety profile and dose coordination details for the bupropion side of the smoking-cessation stack
• GLP-1 and alcohol use disorder evidence — the parallel reward-pathway story for alcohol
• GLP-1 and naltrexone stacking for alcohol use disorder — the mechanism overlap with mu-opioid receptor modulation
• Does bupropion cause weight loss? — the weight-loss side of bupropion as a single agent and inside Contrave

Important disclaimer. This article is educational and does not constitute medical advice. Smoking cessation pharmacotherapy should be individualized and coordinated with a primary care or addiction medicine clinician, particularly for patients with seizure disorder, psychiatric comorbidity, or cardiovascular disease. GLP-1 medications are not FDA-approved for smoking cessation; their use in that indication remains off-label and unconfirmed by Phase 3 trials. Pregnant and breastfeeding patients should not use GLP-1 medications and should discuss NRT vs non-pharmacological cessation strategies with an obstetric clinician. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a Phase 3 trial of semaglutide or tirzepatide for tobacco-use disorder is published.